Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:21:53 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ABEO - ABEONA THERAPEUTICS INC - http://abeonatherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABEO - Q0.16.86·9.110.17.53    9.01  2.83Apr 18Apr 0115 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-01 08:30U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 07:30U:ABEONews ReleaseAbeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
2024-03-05 07:30U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 16:05U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
2024-01-08 07:30U:ABEONews ReleaseAbeona Therapeutics Announces $50 Million Credit Facility
2023-12-15 07:30U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-27 07:30U:ABEONews ReleaseAbeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
2023-11-13 07:30U:ABEONews ReleaseAbeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
2023-11-01 07:30U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-26 07:30U:ABEONews ReleaseAbeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
2023-09-12 07:30U:ABEONews ReleaseAbeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
2023-09-07 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Participation in Upcoming Investor Conferences
2023-08-30 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
2023-08-08 07:30U:ABEONews ReleaseAbeona Therapeutics Reports Second Quarter 2023 Financial Results
2023-07-28 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
2023-07-19 08:30U:ABEONews ReleaseAbeona Therapeutics Joins Rare Disease Company Coalition
2023-07-07 08:30U:ABEONews ReleaseAbeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-07-03 08:45U:ABEONews ReleaseAbeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-06-09 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101